Shares in AcelRx (NSDQ:ACRX) fell last week after U.S. Sen. Ed Markey (D-Mass) called on the FDA to reject the drugmaker’s opioid painkiller, Dsuvia.
The senator noted that the product, which is designed for use in medically-supervised settings, consists of sufentanil – an opioid that is up to 10 times as powerful as fentanyl.
Get the full story at our sister site, Drug Delivery Business News.
The post AcelRx shares fall as Sen. Markey calls on FDA to reject opioid painkiller appeared first on MassDevice.